Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Pharming Group NV
PHARCurrent price
9.75 USD
-0.014 USD (-0.15%)
Last closed
9.81 USD
Company
www.pharming.com
ISIN
US71716E1055
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
614 522 176 USD
Yield for 12 month
-24.74 %
1Y
3Y
5Y
10Y
15Y
PHAR
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Address: Darwinweg 24, Leiden, Netherlands, 2333 CR
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
27.00 USDP/E ratio
–Dividend Yield
–Current Year
+245 316 000 USD
Last Year
+205 622 000 USD
Current Quarter
+75 062 600 USD
Last Quarter
+74 030 646 USD
Current Year
+220 104 000 USD
Last Year
+188 060 000 USD
Current Quarter
+68 224 141 USD
Last Quarter
+66 038 134 USD
Key Figures PHAR
1 year
3 years
5 years
10 years
EBITDA
-3 057 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-1.38 %
PEG Ratio
–
Return On Equity TTM
-8.18 %
Wall Street Target Price
27.00 USD
Revenue TTM
285 744 992 USD
Book Value
0.44 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
12.20 %
Dividend Yield
–
Gross Profit TTM
188 060 000 USD
Earnings per share
-0.27 USD
Diluted Eps TTM
-0.27 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-61.50 %
Profit Margin
-6.24 %
Dividend Analytics PHAR
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PHAR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PHAR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
169.49
Enterprise Value Revenue
2.00
Price Sales TTM
2.15
Enterprise Value EBITDA
75.70
Price Book MRQ
2.67
Financials PHAR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PHAR
For 52 weeks
6.65 USD
13.20 USD
50 Day MA
8.29 USD
Shares Short Prior Month
25 454
200 Day MA
8.83 USD
Short Ratio
3.00
Shares Short
20 262
Short Percent
0.030 %
BeatStart